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Abstract
Background: Lung adenocarcinom (AC) is the most common form of lung cancer. Currently, the number of medical options
to deal with lung cancer is very limited. In this study, we aimed to investigate potential therapeutic compounds for lung
adenocarcinoma based on integrative analysis.
Methodology/Principal Findings: The candidate therapeutic compounds were identified in a two-step process. First, a
meta-analysis of two published microarray data was conducted to obtain a list of 343 differentially expressed genes specific
to lung AC. In the next step, expression profiles of these genes were used to query the Connectivity-Map (C-MAP) database
to identify a list of compounds whose treatment reverse expression direction in various cancer cells. Several compounds in
the categories of HSP90 inhibitor, HDAC inhibitor, PPAR agonist, PI3K inhibitor, passed our screening to be the leading
candidates. On top of the list, three HSP90 inhibitors, i.e. 17-AAG (also known as tanespimycin), monorden, and
alvespimycin, showed significant negative enrichment scores. Cytotoxicity as well as effects on cell cycle regulation and
apoptosis were evaluated experimentally in lung adenocarcinoma cell line (A549 or GLC-82) with or without treatment with
17-AAG. In vitro study demonstrated that 17-AAG alone or in combination with cisplatin (DDP) can significantly inhibit lung
adenocarcinoma cell growth by inducing cell cycle arrest and apoptosis.
Conclusions/Significance: We have used an in silico screening to identify compounds for treating lung cancer. One such
compound 17-AAG demonstrated its anti-lung AC activity by inhibiting cell growth and promoting apoptosis and cell cycle
arrest.
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Introduction
Lung cancer, including small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC), is the leading cause of cancer
deaths for both men and women worldwide, particularly in China
[1],[2],[3],[4]. Lung adenocarcinoma is the predominant histo-
logical subtype of NSCLC and accounts for about 20,30% of
primary lung cancer cases for people under the age of 45
regardless of smoking history [5]. Clinically, surgical resection
remains the most effective treatment for early-stage NSCLC
patients (stage I–II), with 30%–60% of survival 5 years after
intervention [6]. However, five-year survival rate drops to about
10,15% for most NSCLC patients due to late diagnosis, when the
tumor has become unresectable. Chemotherapy using cisplatin
(DDP) in combination with other antitumor agents (e.g.,
paclitaxel, gemcitabine, vinorelbine, etc.) remains the first
treatment plan for advanced NSCLC. In recent years, the use of
some small molecular agents targeting specific tyrosine kinases of
cancer cells shows favorable results, but the improvement is often
insignificant to extend the lives of NSCLC patients. Thus, there is
a need for finding new and effective therapeutic agents for lung
adenocarcinoma.
Gene expression profiling is used as a powerful tool for
elucidating disease-specific molecular mechanism, biological
pathway [7], as well as for predicting drug response or
resistance [8], disease outcome [9], and for discovering new
targets [10]. Recently, Lamb and his coworkers [11] created a
searchable database (‘‘Connectivity Map’’, C-MAP) containing
thousands of gene-expression signatures of various cultured
cancer cells exposed to a large collection of small molecule
compounds. C-MAP represents a useful tool for the discovery
of unexplored connections among small molecules, diseases,
and the biological pathways that join them. By comparing
expression signatures, C-MAP serves as a proxy to search for
new indications of all compounds surveyed, and has seen its
success in drug re-discovery. Using C-MAP, Guo et al identified
rapamycin as a potential glucocorticoid resistance reversal
agent [12]. Two new hsp90 inhibitors, celastrol and gedunin,
were discovered using this approach [13]. In another study,
new therapeutic compounds for treating neuroblastoma were
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potential [15],[16].
In the present study, we set out to discover agents not known for
targeting lung adenocarcinoma by an expression-based in silico
screening. We screened and ranked for genes differentially
expressed in lung adenocarcinoma versus normal lung tissue.
The ranked gene list (denoted as signature) was then submitted to
the C-Map database for the identification of compounds or drugs
reversing the expression direction of the signature. Among the
candidate compounds found, 17-AAG (also known as Tanespi-
mycin) was selected as a potential therapeutic agent for lung
adenomcarcinoma. In subsequent validation experiments, 17-
AAG alone or in combination with cisplatin inhibited lung
adenocarcinoma cell proliferation and induced both cell cycle
arrest and apoptosis.
Results
Genes differentially expressed between lung
adenocarcinoma and normal lung tissue
C-MAP can be used to query gene expression signature against
a collection of microarray expression signatures from cultured
disease-borne human cell lines treated with bioactive small
molecule compounds. Here, we tested whether C-MAP could be
used to identify compounds reversing the expression signature of
lung adenocarcinoma.
The workflow of the meta-analysis of multiple microarray data
sets is shown in Supplementary Figure. S1. In brief, we first
defined a gene expression signature of lung adenocarcinoma by
identifying differentially-expressed genes common to the two data
sets used. 343 such differentially expressed genes with at least a 2-
fold change found by the meta-analysis were used to define a lung
AC signature (Supplementary Figure. S2). This signature includes
93 up-regulated and 250 down-regulated genes. A detailed gene
list can be found in Supplementary Table S2. Gene Set
Enrichment Analysis (GSEA) suggested that several pathways
related to CELL_CYCLE, AKT, PPARA and TIGHT_JUNC-
TION regulation were dysfunctional in lung AC (unpublished
result).
Identification of compounds reverting expression
signature of lung adenocarcinoma
Using a simple pattern-matching algorithm, C-MAP links drugs,
genes and diseases by measuring similarity or dissimilarity in gene-
expression. To identify drugs exerting antitumor effects by causing
a reversal of the gene expression signature of lung adenocarcinoma
to a favorable one, we performed C-MAP analysis by searching for
negatively-correlated gene expression patterns associated with
drug-treated cancer cells [11]. The expression signature of lung
adenocarcinoma described above was used as input query to
compare with those produced from drug treatments in the C-MAP
database. Multiple drugs were identified for having expression
signatures inverse-correlated with that of lung adenocarcinoma
beyond chance. The results were summarized in Table 1. On top
of the list, three HSP90 inhibitors, i.e. 17-AAG, monorden, and
alvespimycin, showed significant negative enrichment.
17-AAG inhibited lung adenocarcinoma cell growth and
enhanced cisplatin cytotoxicity in vitro
To investigate the biological effects of HSP90 inhibition, A549
or GLC-82 cells were cultured in medium containing various
concentration of 17-AAG (0–3.2 mmol/L) or drug-free medium
containing DMSO (0.1% final concentration) and cell viability was
determined by the MTT assay. As shown in Figure 1A and 1B, it
was evident that increasing concentrations of 17-AAG in the
culture medium inhibited the growth of A549 or GLC-82 cells in a
dose dependent manner. The IC50 of 17-AAG and cisplatin for
A549 at 48 h was 0.454 and 69.63 mmol/L, for GLC-82 was
0.273 and 41.32 mmol/L, respectively. The combination of the
two compounds was tested at fixed ratio based on their IC50s for
assessment of their synergy.
To evaluate the cytotoxic effects of combining 17-AAG and
cisplatin in A549 or GLC-82 cells, we compared the growth
inhibition resulted from single or combined treatment by the two
compounds. As shown in Figure.1C and 1D, either 17-AAG or
cisplatin alone inhibited the growth of A549 and GLC-82 cells in a
concentration-dependent manner. The effect was greater when the
two agents were combined, even at the lowest dosage combina-
tion. To determine whether the combination of cisplatin and 17-
AAG in A549 or GLC-82 cells resulted in synergistic effects, the
median effect method analysis of Chou and Talalay was used [17].
The combination index (CI) values are summarized in Table 2, all
of which were below 1, indicating that there exists a synergistic
antiproliferative effects between 17-AAG and cisplatin in A549 or
GLC-82 cells.
17-AAG caused cell cycle arrest and induced cell
apoptosis in lung adenocarcinoma cells
HSP90 is known to be a chaperone for a variety of proteins that
regulate cell cycle and apoptosis [18],[19]. Thus, we asked
whether the antiproliferative activity of 17-AAG was due to cell
cycle arrest, apoptosis, or both. As compared to untreated cells,
A549 cells treated with 17-AAG showed a signifiantly increased
arrest in G2/M phase (p,0.05) and a marginal decrease in S
phase at 24 h (Figure 2 panel A). This suggested that 17-AAG
induced cell cycle arrest by preventing A549 cells from entering
Table 1. Results of Connectivity Map analysis.
Rank
Compound
name n Enrichment p
Drug
category
1 vorinostat 7 20.83 0 HDAC inhibitor
2 trichostatin A 92 20.327 0 HDAC inhibitor
3 tanespimycin 36 20.395 0.00006 hsp90
inhibitor
4 LY-294002 34 20.31 0.00204 PI3K inhibitor
5 alvespimycin 7 20.617 0.00443 hsp90
inhibitor
6 resveratrol 6 20.655 0.00467 phytoalexin
7 thioridazine 4 20.773 0.00539 antipsychotic
8 monorden 12 20.469 0.00615 hsp90
inhibitor
9 15-delta prostaglandin J2 8 20.552 0.00784 PPAR agonist
10 troglitazone 4 20.675 0.02487 PPAR agonist
11 CP-690334-01 4 20.673 0.02558 Not assessed
12 geldanamycin 10 20.43 0.03386 hsp90
inhibitor
13 carbamazepine 5 20.585 0.03609 anticonvulsant
14 pioglitazone 5 20.571 0.04348 PPAR agonist
15 0173570-0000 4 20.632 0.04492 Not assessed
NOTE: The compounds tested in at least four experiments were ranked based
on p value.
doi:10.1371/journal.pone.0014573.t001
Drug Discovery for Lung Cancer
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produce modest to marginal change in S or G2/M arrest as
compared to the respective control groups (Figure 2 panel A).
Annexin-V/PI (propidium iodide) flow cytometric experiments
were performed to determine if 17-AAG alone or in combination
with cisplatin could induce A549 cell apoptosis. Viable cells with
intact membranesexcludePI,whereas dead and damaged cells with
brokenmembranesarepermeabletoPI.Asshown inFigure.2 panel
B, upto 32% of cells treated with 17-AAG became apoptotic
(including early and late apoptosis) as compared to about 12%
apoptotic cells in control (p,0.05) (Figure.2 panel B). When 17-
AAG combined with cisplatin, the percentage of late apoptotic cells,
notably total apoptotic cells, increased as compared to those treated
with 17-AAG alone (p,0.05) (Figure 2 panel B).
Figure 1. Cytotoxic effect of cisplatin (DDP), 17-AAG alone or together in lung adenocarcinoma cell lines. A549 or GLC-82 cells were
incubated with 10,320 mM cisplatin (A), 0.2,3.2 mM 17-AAG (B), or various concentrations of cisplatin in combination with 17-AAG (C, D) at fixed
ratio for 48 h. Cell viability was determined by the MTT assay and expressed as relative viability to control cells. Each bar represents results from
triplicate experiments.
doi:10.1371/journal.pone.0014573.g001
Table 2. Synergy of 17-AAG with cisplatin in growth inhibition of A549 or GLC-82 cells.
A549 cell line GLC-82 cell line
17-AAG( mmol/L) Cisplatin( mmol/L) C I 17-AAG( mmol/L) Cisplatin( mmol/L) C I
0.025 4.4 0.321 0.018 2.5 0.423
0.05 8.7 0.339 0.035 5 0.482
0.1 17.5 0.420 0.07 10 0.597
0.2 35 0.570 0.14 20 0.684
0.4 70 0.697 0.28 40 0.855
NOTE: Combination Index (CI) values for 17-AAG with cisplatin at a constant ratio (1:175) as determined using the method of Chou and Talalay. CI=1: additive effect;
CI,1: synergy; CI.1: antagonism.
doi:10.1371/journal.pone.0014573.t002
Drug Discovery for Lung Cancer
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and RAF-1 mRNA
Many factors including EGFR, HIF-1A, AKT1 and RAF-1 are
known to be regulated by Hsp90 and their abnormal expression level
is often associated with lung cancers [20],[21],[22],[23],[24]. We
assessed the transcription levels of EGFR, HIF-1A, AKT1 and RAF-1
by real-time RT-PCR after A549 or GLC-82 cells were treated with
17-AAGor DMSO for 24 h. ResultsshowedthatthemRNAlevelsof
EGFR, HIF-1A, AKT1 and RAF-1 in 17-AAG-treated A549 or GLC-
82 cells decreased over control (Figure 3A and 3B). 17-AAG down-
regulated expression of EGFR and HIF1A in GLC-82 cells by as
muchas1.81and 1.54-foldrespectively ascompared to those in A549
cells. However, the levels of Raf1 and AKT1 mRNA down-regulated
by 17-AAG was similar in both cell lines.
Figure 2. Effect of 17-AAG on cell cycle assessed using propidium iodide (PI) staining (A) and effect of 17-AAG on cell apoptosis
quantitated using Annexin-V/PI detection (B). The A549 cells were exposed to various concentrations of 17-AAG or various concentrations of
cisplatin in combination with 17-AAG at fixed ratio for 24 h. The cells were harvested and analyzed by flow cytometry. Each bar represents the means
6 S.D (n=3). Groups with significant change as compared to the respective control group were marked with asterisks (* p,0.05). Comparison of 17-
AAG+cisplatin at their highest dosage was made against 17-AAG2treated groups and was found to be significant (# p,0.05) in terms of late/total
apoptosis. G1: G1 phase; S: S phase; G2/M: G2/M phase.
doi:10.1371/journal.pone.0014573.g002
Figure 3. Expression of EGFR, HIF1A, AKT1 and RAF1 mRNA was determined by real time RT-PCR after A549 (A) or GLC-82 (B) cells
were treated with 17-AAG or DMSO for 24 h.
doi:10.1371/journal.pone.0014573.g003
Drug Discovery for Lung Cancer
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Using an expression signature specific to lung adenocarcinoma, a
number of compounds from C-MAP analysis were identified for
having negatively-correlated effects on expression of query
signature. These include HSP90 inhibitors, HDAC inhibitors,
PPAR agonists, PI3K inhibitors, etc (Table 1). Some of the top hits
in our initial screening, including histone deacetylase inhibitor
trichostatin A [25], peroxisome proliferator-activated receptor
agonist 15-delta prostaglandin J2, and PI3K inhibitor LY-294002,
all have been shown to possess promising therapeutic activity for
treatingmanycancertypes inludinglung cancer[26],[27],[28],[29].
17-AAG, one of the three top-ranked HSP90 inhibitors (17-AAG,
monorden and alvespimycin), prevented proliferation of lung AC,
induced G2/M cell cycle arrest and apoptosis in subsequent
validation experiments as expected. When combined with the
commonly-prescribed cisplatin, 17-AAG also showed synergistic
interaction in inhibiting cell proliferation. These results agree with
the rational behind our approach in finding new uses of existing
compounds for unexplored medical conditions. In fact, this
approach has been proved to be valuable in the area of drug
discovery by others [12],[13],[14].
The constitutively action of PI3K/Akt signal transduction
pathway has been reported to promote survival and proliferation
ofNSCLCs[23],[30],[31].Akt,a downstreamtargetofPI3k,isoften
mutated and amplified in a variety of human tumors including
about 50% of NSCLC tissues [30]. C-RAF (Raf-1), which is a
component of the RAS/RAF/MEK/ERK pathway, also overex-
pressed in NSCLCs [32]. The alterations of some transmembrane
receptors or signaling factors may result in the activation of PI3K/
Akt signal pathway. For example, EGFR, which overexpressed in
40–80% of NSCLC, is an important up-stream regulator of PI3K/
Akt [23] and RAS/RAF/MEK/ERK pathway in lung cancers
[32]. In addition, the stabilization and activation of hypoxia-
inducible transcription factor-1 (HIF-1), which contributed to the
promotion of angiogenesis and the therapeutic resistance of tumor
cells, can be affected by RAS/RAF/MEK/ERK and PI3K/Akt
signal transduction pathways [21].
Hsp90 is a highly conserved molecular chaperone important for
regulating a subset of cellular proteins. For example, it is critical
for the maturation and conformational stabilization of proteins of
normal cellular functions and those implicated in oncogenesis (e.g.,
Akt, HER2, Raf-1, HIF-1A, EGFR and Cdk4) [22],[33]. We
speculate that 17-AAG exercises its inhibitory effect by reducing
Hsp90 proteins activity and thereby destabilizing proteins
important for cancer cell growth. Correlated with the observed
growth inhibition, 17-AAG caused down-regulation of EGFR,
HIF-1A, AKT1 and RAF1, with a much deeper inhibition of EGFR
and HIF-1A expression in GLC-82 than that in A549. Previous
studies have demonstrated that various Hsp90 inhibitors (e.g.17-
AAG, 17DMAG) caused the inhibition and interference of
oncogenic signaling cascades in other advanced cancers by
degrading EGFR, Akt, Raf-1 and HIF-1A, or by decreasing their
expression [21],[23],[30],[32]. Here, we demonstrated that 17-
AAG has similar effect in lung AC cells (Fig. 3A and B), which may
result in growth inhibition, cell cycle arrest and apoptosis.
As shown in this study, A549 cells were found to arrest in G2/M
after exposure to 17-AAG. The overall effect of 17-AAG on cell
cycle regulation depends on cancer type or even cell lines, a
reminiscence of G1 or G2/M arrest or both seen in different types
of cancer cell lines [34]. In prostate cancer cell line, 17-AAG
induced G1 arrest by degradating HER2, Akt, and androgen
receptor [24]. In two different hepatoma cell lines, 17-AAG
induced G1 and G2/M arrest in HuH7 and arrest only in G2/M in
Hep3B cell lines, which owed to the difference of Akt expression in
these cells [35]. However, 17-AAG and cisplatin have no synergy
on cell cycle inhibition, which might be resulted from 17-AAG’s
effect being masked by cisplatin’s effect in the preceding S phase.
Identifying new compounds for medical conditions is generally
time-consuming and very expensive. We explore an in silico
strategy to discover new uses of existing compounds for unmet
clinical needs. A pre-requisite for the success of this approach is the
availability of a high quality expression signature. This signature
should mirror the changes between normal and diseased states to a
reasonably good degree. To reduce the risk of bias, we selected our
signature through meta-analysis. Meta-analysis provides more
analytical power for us to generate such a more representative
signature. Another major hurdle is the coverage of C-Map which
currently contains over 7000 expression signatures with about
1300 compounds tested for four cell types. This may not be
enough to deal with the complexity of many human diseases. In
addition, only limited number of genes are allowed as input. This
may distort pattern matching process if bias is present. When
evaluating screening result, one needs to bear in mind that the
connectivity score is merely a statistical measure of similarity or
dissimilarity, as it is easier to obtain higher connectivity scores in a
relatively low number of experimental instances. To be on the safe
side, we initially filtered the compounds tested less than four times,
and prioritized candidate compounds based on both p-value and
the number of compounds in each class (Table 1).
In summary, our study demonstrated that gene expression
signature-based in silico drug discovery is potentially valuable for
the identification of new indications of existing compounds, which
is critical for translational research and clinical applications. One
major advantage of such approach is that the time-to-market is
much shorter and cost-saving is significant as compared to new
drug development since many compounds assayed in C-Map are
approved by the Food and Drug Administration. Any promising
drug(s) from such screen could be particularly beneficial to patients
whose medical conditions have no effective treatment. 17-AAG is
currently being evaluated for the treatment of multiple cancer
indications in Phase I and Phase II clinical trials. Its anti-tumor
activity in lung cancer has not been included in on-going trials but
could be verified in subsequent trials, subjecting to more in-depth
studies and structural optimization.
Materials and Methods
Compounds and Cell culture
17-AAG (17-Allylamino-17-demethoxygeldanamycin), obtained
from Sigma- Aldrich (St. Louis, MO), was dissolved in dimethyl-
sulfoxide (DMSO) to a 10 mMol/L stock concentration and stored
at 220uC. The maximum volume (%) of DMSO in the
experiment was less than 0.1%, and equal concentrations of
DMSO alone served as a control in all experiments. Water-soluble
cisplatin (DDP), also from Sigma-Aldrich (St. Louis, MO), was
dissolved in PBS to a concentration of 0.1 mol/L and stored at
220uC. Two human lung adenocarcinoma cell lines A549 and
GLC-82 (see Table S3 for more details) were obtained from
GuangZhou Medical College cell repository and SUN YAT-SEN
University cell repository, respectively. Cells were cultured in
RPMI1640 medium supplemented with 10% fetal bovine serum
(Invitrogen-Life Technologies, Inc.) at 37uC in the presence of 5%
CO2.
Acquisition and analysis of public microarray data
Raw data (.Cel files) of two published microarray data
(GSE7670 and GSE10072) used in this study were obtained from
Drug Discovery for Lung Cancer
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Expression Omnibus (GEO) web site (http://www.ncbi.nlm.nih.
gov/geo).
Details of the two microarray datasets are summarized in
Supplementary Table S1. Microarray analysis was done with the
BRB Array Tools (Version: 3.7.0), developed by the Biometric
Research Branch of the US National Cancer Institute (http://
linus.nci.nih.gov/BRB-ArrayTools.html). Two-sample T-test was
used to identify differential genes. To control type I error, a total of
2,000 permutations were performed to set an upper limit of false
discovery rate (FDR) to ,1% at 95% confidence level. Differential
expression was considered significant using a 2-fold change cutoff.
Finally, differential probe IDs common to the two data sets were
obtained as the lung AC signature for further C-MAP analysis.
Connectivity Map analysis
C-Map (build02, http://www.broad.mit.edu/cmap/) contains
more than 7,000 expression signatures representing 1,309
compounds. Up and down-regulated gene groups were submitted
simultaneously to C-MAP for analysis. Enrichment scores for each
and every compound in the database were computed using the
gene set enrichment analysis algorithm [11]. Compounds with
negative connectivity scores, which imply a mode of action by the
matched compounds to reverse the expression direction of query
genes in lung adenocarcinoma, were recorded as potential
therapeutic agents for lung adenocarcinoma.
Cell viability and toxicity assay
To evaluate cytotoxic effects of 17-AAG on lung adenocarci-
noma cells, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide assay (MTT) was performed as previously described
[12]. In brief, A549 cells or GLC-82 (4610
4 cells/ml) were seeded
in triplicate into 96-well plates (Costar, Corning, NY). After
overnight incubation, cells were incubated in drug-free medium,
or medium containing various concentrations of 17-AAG, or 17-
AAG in combination with cisplatin for 48 h at 37uC. After drug
exposure for the indicated concentrations and times, cells were
incubated at 37uC for 4 h with the addition of 10 ml of MTT
labeling reagent. Following MTT incubation, the absorbance of
the samples was determined by a microplate reader at 490 nm
(Tecan Sunrise, Switzerland). All experiments were performed at
least three times for each experimental condition, and results were
shown as relative ratios of viability in the treated over control
groups. To confirm the synergistic cytotoxic interaction effect of
cisplatin and 17-AAG, the combination index (CI) was calculated
by Calcusyn Software (Biososoft, Ferguson, MO) according to the
Chou-Talala method [12],[13]. Combination index values less
than 1, equal to 1, or more than 1 indicate synergistic, additive, or
antagonistic cytotoxic drug interactions, respectively.
Cell cycle and cell apoptosis assays
Cell cycle and apoptosis assays were done as previously
described [35]. In brief, cells were plated in duplicate into 6-well
microplates at 5610
6 cells/well, and incubated in drug-free
medium or medium containing 17-AAG, or 17-AAG plus cisplatin
of varying concentrations at 37uC for 24 h. For cellular DNA
content assay, cells were collected and washed with ice-cold PBS,
fixed with 70% ethanol at 4uC for 1 h. After washing, cells were
treated with RNase (0.25 mg/mL) for 30 min and stained with
50 g/mL of propidium iodide (PI). Stained cells were kept on ice
and protected from light. Cell cycle analysis was performed with
FACScan flow cytometer (Becton Dickinson, USA) and the
percentage of cells in the G1, S and G2/M phases of the cell
cycle was determined using the ModfitLT software program
(Becton Dickinson). For Annexin V staining, cells were washed
once with PBS and then 10 mL of Annexin V-FITC solution and
5 mL of PI solution were added. After 15 minutes of incubation
away from light, cells were directly analyzed by FACScan and
evaluated by the CellQuest program.
Real-Time reverse transcription-PCR
A549 or GLC-82 cells were treated with 0.45 mM 17-AAG or
DMSO for 24 h and total RNAs were isolated with Trizol
(Invitrogen, Karlsruhe, Germany), 18S rRNA gene was used as
the internal normalization control. Real-time RT-PCR(qRT-
PCR) was performed on an ABI Prism 7300 Sequence Detection
System (Applied Biosystems) in a 96-well reaction plate according
to the manufacturer’s recommendations. The PCR amplification
protocol was as follows: 95uC for 5 min, followed by 40 cycles of
95uC for 15 s, 60uC for 15 s and 72uC for 30 s. Each PCR
reaction was performed in triplicate and the experiments were
repeated three times. PCR product quality was monitored using
post-PCR melt curve analysis. Fold inductions were calculated
using the formula 2-
(ggct), where ggCt is gCt(treatment)
2gCt(control), gCt is Ct(target gene) 2Ct(18sRNA) and Ct is the cycle
at which the threshold is crossed [36]. The primers used for real-
time PCR are as follows:
EGFR: 5-ACTACAGGTCAAGTGGTAGC-3(forward) and
5- GAGGAGGAGTATGTGTGAAGGA -3 (reverse)
HIF 1A: 5- GTGGATTACCACAGCTGA -3 (forward) and
5- GCTCAGTTAACTTGATCCA -3(reverse)
AKT1: 5- TCTGTCACCAGCTATCTG -3(forward) and
5-GACAGTCACCAAGAACTG-3(reverse);
RAF-1: 5- CTGCTTTGGTACTATGGAAC-3 (forward) and
5- TTCAGCATGATGGAAGACTG -3 (reverse)
18srRNA: 5- CCTGGATACCGCAGCTAGGA-3 (forward)
and
5- GCGGCGCAATACGAATGCCCC -3 (reverse)
Statistical analysis
The statistical significance of cell cycle distributions and
apoptosis between groups were assessed with one-way ANOVA
followed by post-hoc LSD and Dunnett T3 test using the SPSS
software (version 13.0). p values of ,0.05 were considered to be
significant.
Supporting Information
Figure S1 The workflow of the meta-analysis of microarray data
sets. Meta-analysis was done with the BRB Array Tools. Intensity
filtering was used in individual arrays for quality-control purposes
before arrays are normalized. Signal intensity threshold was set to
1 by default. The median-normalization was used for data
normalization. Class comparison between groups of arrays was
used to find genes that are differentially expressed between two
phenotype classes, whereas two-sample T-test was used as type of
univariate test.
Found at: doi:10.1371/journal.pone.0014573.s001 (1.61 MB TIF)
Figure S2 Venn diagram for the resultant genes. Analysis of
GSE7670 produced 434 differential genes (125 up and 309 down),
and analysis of GSE10072 identified 530 differential genes (180 up
and 350 down). 343 genes (A) were found common from the two
result sets, including 93 up-regulated (B) and 250 down-regulated
genes (C).
Found at: doi:10.1371/journal.pone.0014573.s002 (1.51 MB TIF)
Table S1 Summary of the two microarray datasets, GSE7670
and GSE10072. There are 66 samples in dataset GSE7670, 107
Drug Discovery for Lung Cancer
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e14573samples in dataset GSE10072. We selected 54 paired samples from
27 patients in dataset GSE7670, 62 paired samples from 31
patients in dataset GSE10072.
Found at: doi:10.1371/journal.pone.0014573.s003 (0.03 MB
XLS)
Table S2 Lung adenocarcinoma signature genes. This signature
includes 93 up-regulated and 250 down-regulated genes.
Found at: doi:10.1371/journal.pone.0014573.s004 (0.05 MB
XLS)
Table S3 Cytogenetic information of two human lung adeno-
carcinoma cell lines, GLC-82 and A549.
Found at: doi:10.1371/journal.pone.0014573.s005 (0.03 MB
DOC)
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